TAK
insider transactionsTAKEDA PHARMACEUTICAL CO LTD — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
President and CEO
$0
79.0K sh
Own +170%
-
Grant·A
President and CEO
$0
165.4K sh
Own +65%
-
Grant·A
President and CEO
$0
78.9K sh
Own +8%
-
Grant·A
Chief Data & Tech. Officer
$0
35.0K sh
Own +28%
-
Grant·A
President, R&D
$0
212.5K sh
Own +36%
-
Grant·A
President, IBU
$0
72.1K sh
Own +32%
-
Grant·A
Head, Strat. & Port. Dev.
$0
27.7K sh
Own +19%
-
Grant·A
CEO - Elect
$0
105.4K sh
Own +32%
-
Grant·A
Milano Furuta KEY
Chief Financial Officer
$0
7.8K sh
Own +89%
-
Grant·A
Milano Furuta KEY
Chief Financial Officer
$0
7.8K sh
Own +16%
-
Grant·A
Chief Transformation Officer
$0
60.0K sh
Own +36%
-
Grant·A
President, OBU
$0
65.0K sh
Own +34%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 27, 2026 | Weber Christophe Pierre KEY | Grant A | 79.0K | $0 |
| Apr 27, 2026 | Weber Christophe Pierre KEY | Grant A | 165.4K | $0 |
| Apr 27, 2026 | Weber Christophe Pierre KEY | Grant A | 78.9K | $0 |
| Apr 27, 2026 | Gabriele Ricci | Grant A | 35.0K | $0 |
| Apr 27, 2026 | Andrew Stewart Plump KEY | Grant A | 212.5K | $0 |
| Apr 27, 2026 | Giles Richard Platford KEY | Grant A | 72.1K | $0 |
| Apr 27, 2026 | Agosti Marcello Pignagnoli | Grant A | 27.7K | $0 |
| Apr 27, 2026 | Julie So-Young Kim KEY | Grant A | 105.4K | $0 |
| Apr 27, 2026 | Milano Furuta KEY | Grant A | 7.8K | $0 |
| Apr 27, 2026 | Milano Furuta KEY | Grant A | 7.8K | $0 |
| Apr 27, 2026 | Lauren Rusckowski Duprey | Grant A | 60.0K | $0 |
| Apr 27, 2026 | Bitetti Teresa Marie KEY | Grant A | 65.0K | $0 |
About TAK insider trading
This page tracks insider transactions for TAKEDA PHARMACEUTICAL CO LTD (TAK) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.